- •Hematuria II: causes and investigation
- •Hematospermia
- •Lower urinary tract symptoms (LUTS)
- •Nocturia and nocturnal polyuria
- •Flank pain
- •Urinary incontinence in adults
- •Genital symptoms
- •Abdominal examination in urological disease
- •Digital rectal examination (DRE)
- •Lumps in the groin
- •Lumps in the scrotum
- •2 Urological investigations
- •Urine examination
- •Urine cytology
- •Radiological imaging of the urinary tract
- •Uses of plain abdominal radiography (KUB X-ray—kidneys, ureters, bladder)
- •Intravenous pyelography (IVP)
- •Other urological contrast studies
- •Computed tomography (CT) and magnetic resonance imaging (MRI)
- •Radioisotope imaging
- •Post-void residual urine volume measurement
- •3 Bladder outlet obstruction
- •Regulation of prostate growth and development of benign prostatic hyperplasia (BPH)
- •Pathophysiology and causes of bladder outlet obstruction (BOO) and BPH
- •Benign prostatic obstruction (BPO): symptoms and signs
- •Diagnostic tests in men with LUTS thought to be due to BPH
- •Why do men seek treatment for their symptoms?
- •Watchful waiting for uncomplicated BPH
- •Medical management of BPH: combination therapy
- •Medical management of BPH: alternative drug therapy
- •Minimally invasive management of BPH: surgical alternatives to TURP
- •Invasive surgical alternatives to TURP
- •TURP and open prostatectomy
- •Indications for and technique of urethral catheterization
- •Indications for and technique of suprapubic catheterization
- •Management of nocturia and nocturnal polyuria
- •High-pressure chronic retention (HPCR)
- •Bladder outlet obstruction and retention in women
- •Urethral stricture disease
- •4 Incontinence
- •Causes and pathophysiology
- •Evaluation
- •Treatment of sphincter weakness incontinence: injection therapy
- •Treatment of sphincter weakness incontinence: retropubic suspension
- •Treatment of sphincter weakness incontinence: pubovaginal slings
- •Overactive bladder: conventional treatment
- •Overactive bladder: options for failed conventional therapy
- •“Mixed” incontinence
- •Post-prostatectomy incontinence
- •Incontinence in the elderly patient
- •Urinary tract infection: microbiology
- •Lower urinary tract infection
- •Recurrent urinary tract infection
- •Urinary tract infection: treatment
- •Acute pyelonephritis
- •Pyonephrosis and perinephric abscess
- •Other forms of pyelonephritis
- •Chronic pyelonephritis
- •Septicemia and urosepsis
- •Fournier gangrene
- •Epididymitis and orchitis
- •Periurethral abscess
- •Prostatitis: presentation, evaluation, and treatment
- •Other prostate infections
- •Interstitial cystitis
- •Tuberculosis
- •Parasitic infections
- •HIV in urological surgery
- •6 Urological neoplasia
- •Pathology and molecular biology
- •Prostate cancer: epidemiology and etiology
- •Prostate cancer: incidence, prevalence, and mortality
- •Prostate cancer pathology: premalignant lesions
- •Counseling before prostate cancer screening
- •Prostate cancer: clinical presentation
- •PSA and prostate cancer
- •PSA derivatives: free-to-total ratio, density, and velocity
- •Prostate cancer: transrectal ultrasonography and biopsies
- •Prostate cancer staging
- •Prostate cancer grading
- •General principles of management of localized prostate cancer
- •Management of localized prostate cancer: watchful waiting and active surveillance
- •Management of localized prostate cancer: radical prostatectomy
- •Postoperative course after radical prostatectomy
- •Prostate cancer control with radical prostatectomy
- •Management of localized prostate cancer: radical external beam radiotherapy (EBRT)
- •Management of localized prostate cancer: brachytherapy (BT)
- •Management of localized and radiorecurrent prostate cancer: cryotherapy and HIFU
- •Management of locally advanced nonmetastatic prostate cancer (T3–4 N0M0)
- •Management of advanced prostate cancer: hormone therapy I
- •Management of advanced prostate cancer: hormone therapy II
- •Management of advanced prostate cancer: hormone therapy III
- •Management of advanced prostate cancer: androgen-independent/ castration-resistant disease
- •Palliative management of prostate cancer
- •Prostate cancer: prevention; complementary and alternative therapies
- •Bladder cancer: epidemiology and etiology
- •Bladder cancer: pathology and staging
- •Bladder cancer: presentation
- •Bladder cancer: diagnosis and staging
- •Muscle-invasive bladder cancer: surgical management of localized (pT2/3a) disease
- •Muscle-invasive bladder cancer: radical and palliative radiotherapy
- •Muscle-invasive bladder cancer: management of locally advanced and metastatic disease
- •Bladder cancer: urinary diversion after cystectomy
- •Transitional cell carcinoma (UC) of the renal pelvis and ureter
- •Radiological assessment of renal masses
- •Benign renal masses
- •Renal cell carcinoma: epidemiology and etiology
- •Renal cell carcinoma: pathology, staging, and prognosis
- •Renal cell carcinoma: presentation and investigations
- •Renal cell carcinoma: active surveillance
- •Renal cell carcinoma: surgical treatment I
- •Renal cell carcinoma: surgical treatment II
- •Renal cell carcinoma: management of metastatic disease
- •Testicular cancer: epidemiology and etiology
- •Testicular cancer: clinical presentation
- •Testicular cancer: serum markers
- •Testicular cancer: pathology and staging
- •Testicular cancer: prognostic staging system for metastatic germ cell cancer
- •Testicular cancer: management of non-seminomatous germ cell tumors (NSGCT)
- •Testicular cancer: management of seminoma, IGCN, and lymphoma
- •Penile neoplasia: benign, viral-related, and premalignant lesions
- •Penile cancer: epidemiology, risk factors, and pathology
- •Squamous cell carcinoma of the penis: clinical management
- •Carcinoma of the scrotum
- •Tumors of the testicular adnexa
- •Urethral cancer
- •Wilms tumor and neuroblastoma
- •7 Miscellaneous urological diseases of the kidney
- •Cystic renal disease: simple cysts
- •Cystic renal disease: calyceal diverticulum
- •Cystic renal disease: medullary sponge kidney (MSK)
- •Acquired renal cystic disease (ARCD)
- •Autosomal dominant (adult) polycystic kidney disease (ADPKD)
- •Ureteropelvic junction (UPJ) obstruction in adults
- •Anomalies of renal ascent and fusion: horseshoe kidney, pelvic kidney, malrotation
- •Renal duplications
- •8 Stone disease
- •Kidney stones: epidemiology
- •Kidney stones: types and predisposing factors
- •Kidney stones: mechanisms of formation
- •Evaluation of the stone former
- •Kidney stones: presentation and diagnosis
- •Kidney stone treatment options: watchful waiting
- •Stone fragmentation techniques: extracorporeal lithotripsy (ESWL)
- •Intracorporeal techniques of stone fragmentation (fragmentation within the body)
- •Kidney stone treatment: percutaneous nephrolithotomy (PCNL)
- •Kidney stones: open stone surgery
- •Kidney stones: medical therapy (dissolution therapy)
- •Ureteric stones: presentation
- •Ureteric stones: diagnostic radiological imaging
- •Ureteric stones: acute management
- •Ureteric stones: indications for intervention to relieve obstruction and/or remove the stone
- •Ureteric stone treatment
- •Treatment options for ureteric stones
- •Prevention of calcium oxalate stone formation
- •Bladder stones
- •Management of ureteric stones in pregnancy
- •Hydronephrosis
- •Management of ureteric strictures (other than UPJ obstruction)
- •Pathophysiology of urinary tract obstruction
- •Ureter innervation
- •10 Trauma to the urinary tract and other urological emergencies
- •Renal trauma: clinical and radiological assessment
- •Renal trauma: treatment
- •Ureteral injuries: mechanisms and diagnosis
- •Ureteral injuries: management
- •Bladder and urethral injuries associated with pelvic fractures
- •Bladder injuries
- •Posterior urethral injuries in males and urethral injuries in females
- •Anterior urethral injuries
- •Testicular injuries
- •Penile injuries
- •Torsion of the testis and testicular appendages
- •Paraphimosis
- •Malignant ureteral obstruction
- •Spinal cord and cauda equina compression
- •11 Infertility
- •Male reproductive physiology
- •Etiology and evaluation of male infertility
- •Lab investigation of male infertility
- •Oligospermia and azoospermia
- •Varicocele
- •Treatment options for male factor infertility
- •12 Disorders of erectile function, ejaculation, and seminal vesicles
- •Physiology of erection and ejaculation
- •Impotence: evaluation
- •Impotence: treatment
- •Retrograde ejaculation
- •Peyronie’s disease
- •Priapism
- •13 Neuropathic bladder
- •Innervation of the lower urinary tract (LUT)
- •Physiology of urine storage and micturition
- •Bladder and sphincter behavior in the patient with neurological disease
- •The neuropathic lower urinary tract: clinical consequences of storage and emptying problems
- •Bladder management techniques for the neuropathic patient
- •Catheters and sheaths and the neuropathic patient
- •Management of incontinence in the neuropathic patient
- •Management of recurrent urinary tract infections (UTIs) in the neuropathic patient
- •Management of hydronephrosis in the neuropathic patient
- •Bladder dysfunction in multiple sclerosis, in Parkinson disease, after stroke, and in other neurological disease
- •Neuromodulation in lower urinary tract dysfunction
- •14 Urological problems in pregnancy
- •Physiological and anatomical changes in the urinary tract
- •Urinary tract infection (UTI)
- •Hydronephrosis
- •15 Pediatric urology
- •Embryology: urinary tract
- •Undescended testes
- •Urinary tract infection (UTI)
- •Ectopic ureter
- •Ureterocele
- •Ureteropelvic junction (UPJ) obstruction
- •Hypospadias
- •Normal sexual differentiation
- •Abnormal sexual differentiation
- •Cystic kidney disease
- •Exstrophy
- •Epispadias
- •Posterior urethral valves
- •Non-neurogenic voiding dysfunction
- •Nocturnal enuresis
- •16 Urological surgery and equipment
- •Preparation of the patient for urological surgery
- •Antibiotic prophylaxis in urological surgery
- •Complications of surgery in general: DVT and PE
- •Fluid balance and management of shock in the surgical patient
- •Patient safety in the operating room
- •Transurethral resection (TUR) syndrome
- •Catheters and drains in urological surgery
- •Guide wires
- •JJ stents
- •Lasers in urological surgery
- •Diathermy
- •Sterilization of urological equipment
- •Telescopes and light sources in urological endoscopy
- •Consent: general principles
- •Cystoscopy
- •Transurethral resection of the prostate (TURP)
- •Transurethral resection of bladder tumor (TURBT)
- •Optical urethrotomy
- •Circumcision
- •Hydrocele and epididymal cyst removal
- •Nesbit procedure
- •Vasectomy and vasovasostomy
- •Orchiectomy
- •Urological incisions
- •JJ stent insertion
- •Nephrectomy and nephroureterectomy
- •Radical prostatectomy
- •Radical cystectomy
- •Ileal conduit
- •Percutaneous nephrolithotomy (PCNL)
- •Ureteroscopes and ureteroscopy
- •Pyeloplasty
- •Laparoscopic surgery
- •Endoscopic cystolitholapaxy and (open) cystolithotomy
- •Scrotal exploration for torsion and orchiopexy
- •17 Basic science of relevance to urological practice
- •Physiology of bladder and urethra
- •Renal anatomy: renal blood flow and renal function
- •Renal physiology: regulation of water balance
- •Renal physiology: regulation of sodium and potassium excretion
- •Renal physiology: acid–base balance
- •18 Urological eponyms
- •Index
554 CHAPTER 15 Pediatric urology
Abnormal sexual differentiation
Disorders of sex development (DSD) are defined as congenital conditions in which the development of chromosomal, gonadal, or anatomical sex is atypical.
They are estimated to affect 1 in 4500 births, and have recently undergone changes in recommended nomenclature (Table 15.1).1
Sex chromosome DSD (disorders of gonadal differentiation)
These are subdivided into seminiferous tubule dysgenesis (Klinefelter syndrome XXY, 46XX males); Turner syndrome (45XO); true hermaphrodites (46XX or XY with both ovarian and testicular tissue); mixed gondal dysgenesis (streak gonads and a spectrum of ambiguous genitalia); and pure gonadal dysgenesis (females with streak gonads).
46XY DSD (previously male pseudohermaphroditism)
Individuals have 46XY karyotype with differentiated testes. They have defects of testosterone production (3A-hydroxysteroid dehydrogenase, 17A-hydroxylase enzyme deficiencies) or androgen resistance (testicular feminization, 5A-reductase deficiency), resulting in varying degrees of feminization.
46XX DSD (previously female pseudohermaphroditism)
Individuals have 46XX karyotype with ovaries, a partially masculinized phenotype, and ambiguous genitalia. The most common type is congential adrenal hyperplasia (CAH), due to 21-hydroxylase deficiency (in 95%; see Fig. 15.7). Formation of hydrocortisone is impaired, resulting in a compensatory increase in adrenocorticotrophin hormone (ACTH) and testosterone production.
Some forms have a salt-wasting aldosterone deficiency that can present in the first few weeks of life with adrenal crisis (severe vomiting and dehydration), requiring rehydration and steroid replacement therapy.
Evaluation
A detailed history may uncover a positive family history of intersex disorders. Maternal ingestion of drugs such as steroids or contraceptives during pregnancy should be ascertained.
General examination may show associated syndrome anomalies (Klinefelter and Turner syndromes) or failure to thrive and dehydration (salt-wasting CAH). Assess external genitalia for phallus size and location of urethral meatus. Careful palpation may confirm the presence of testes, excluding a diagnosis of female pseudohermaphroditism. Patients with bilateral undescended testes or unilateral undescended testis with hypospadias should be suspected of having an intersex disorder.
Pelvic US can help locate the gonads or, occasionally, laparotomy with gonadal biopsy is required for diagnosis.
1 Hughes IA, Houk C, Ahmed SF, et al. (2007). Consensus statement on management of intersex disorders. Arch Dis Child 554–563.
|
|
ABNORMAL SEXUAL DIFFERENTIATION |
555 |
|
|
Table 15.1 Proposed revised nomenclature* |
|||
|
|
|
|
|
|
Previous terminology |
Proposed new terminology (2007) |
||
|
|
|
|
|
|
Intersex |
Disorders of sex development (DSD) |
||
|
Male pseudohermaphrodite |
46,XY DSD |
||
|
Female pseudohermaphrodite |
46,XX DSD |
||
|
True hermaphrodite |
Ovotesticular DSD |
||
|
Testicular feminization |
Androgen insensitivity syndrome, |
||
|
|
complete (CAIS) |
||
|
46XX male |
46XX testicular DSD |
||
|
|
|
|
|
* Hughes IA, Houk C, Ahmed SF, et al. (2007). Consensus statement on management of intersex disorders. Arch Dis Child 554–563.
Cholesterol
17A-OH
Pregnenolone 17-OH Pregnenolone Dehydroepiandrosterone
|
3B-HSD |
|
3B-HSD |
|
3B-HSD |
|
||
|
|
|
17A-OH |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Progesterone |
|
17-OH Progesterone |
Androstenedione |
|
||||
|
|
|||||||
|
21-OH |
|
21-OH |
|
17B-HSD |
|
||
|
|
|
|
|||||
|
|
|
|
|
|
|
|
|
Deoxycorticosterone |
11-Deoxycortisol |
Testosterone |
|
|||||
|
11B-OH |
|
11B-OH |
|
Intracellular |
|
||
|
|
|
|
|||||
|
|
|
5A-reductase |
|
||||
Corticosterone |
Cortisol |
|
|
|
||||
|
|
|
|
|
|
Dihydrotestosterone |
|
|
|
|
|
|
|
|
|
||
|
|
|
|
|
|
|
|
|
Aldosterone |
|
|
|
|
|
|||
Key: |
|
|
|
|
|
|
|
|
17-OH |
17A-hydroxylase enzyme |
|
|
|
||||
21-OH* |
21-hydroxylase |
|
|
|
|
|
||
3B-HSD |
3B-hydroxysteriod dehydrogenase |
|
|
|
||||
11B-OH |
11B-hydroxylase |
|
|
|
|
|
Figure 15.7 Metabolic pathways for adrenal steroid synthesis.
556 CHAPTER 15 Pediatric urology
Chromosomal analysis confirms karyotype. Serum electrolytes, testosterone, and DHT analysis test for salt-wasting CAH. Serum 17-hydrox- yprogesterone performed after day 3 can also diagnose 21-hydroxylase deficiency, and hCG stimulation test can diagnose androgen resistance and 5A-reductase deficiency.
Management
A multidisciplinary approach is required with full parental input. Gender assignment of ambiguous genitalia is guided by the functional potential of gonadal tissue, reproductive tracts, and genitalia, with the aim of optimizing psychosocial well-being and producing a stable gender identity.
Patients have a higher risk of gonadal malignancy, which requires surveillance and/or removal of gonadal tissues and hormone replacement.
This page intentionally left blank